Compare Stocks → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AXLANASDAQ:MIRONASDAQ:OKYONASDAQ:PLUR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXLAAxcella Health$0.40-8.9%$0.84$0.34▼$41.25$1.18M0.46267,009 shs6,700 shsMIROMiromatrix Medical$3.39$3.38$0.91▼$4.35$92.95M0.0180,095 shsN/AOKYOOKYO Pharma$1.40-4.5%$1.45$0.92▼$3.25$40.36M0.04159,871 shs12,732 shsPLURPluri$5.23+3.6%$6.53$3.45▼$8.56$27.09M1.4525,845 shs18,719 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXLAAxcella Health0.00%0.00%0.00%0.00%-96.17%MIROMiromatrix Medical0.00%0.00%0.00%0.00%+162.79%OKYOOKYO Pharma+4.26%+10.53%-0.34%-9.26%+17.60%PLURPluri-2.32%-12.93%-33.20%+9.74%-32.81%The “Perfect Storm” for Gold (Ad)Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAXLAAxcella HealthN/AN/AN/AN/AN/AN/AN/AN/AMIROMiromatrix MedicalN/AN/AN/AN/AN/AN/AN/AN/AOKYOOKYO Pharma1.6026 of 5 stars3.53.00.00.00.61.70.6PLURPluriN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXLAAxcella HealthN/AN/AN/AN/AMIROMiromatrix MedicalN/AN/A$3.00-11.50% DownsideOKYOOKYO Pharma3.00Buy$7.00400.00% UpsidePLURPluriN/AN/AN/AN/ACurrent Analyst RatingsLatest AXLA, MIRO, OKYO, and PLUR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/22/2024OKYOOKYO PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$6.00 ➝ $7.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXLAAxcella HealthN/AN/AN/AN/A$1.42 per shareN/AMIROMiromatrix Medical$958.03K97.02N/AN/A$1.25 per share2.71OKYOOKYO PharmaN/AN/AN/AN/A($0.08) per shareN/APLURPluri$290K93.42N/AN/A$2.97 per share1.76Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXLAAxcella Health-$81.19M-$19.25N/A∞N/AN/AN/A-259.91%N/AMIROMiromatrix Medical-$29.96M-$1.14N/A∞N/A-2,861.17%-120.49%-90.70%N/AOKYOOKYO Pharma-$13.27MN/A0.00N/AN/AN/AN/AN/A8/20/2024 (Estimated)PLURPluri-$28.32M-$4.64N/A∞N/A-6,708.40%-177.94%-49.60%5/14/2024 (Estimated)Latest AXLA, MIRO, OKYO, and PLUR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/12/2024Q2 2024PLURPluriN/A-$0.96-$0.96-$0.12N/A$0.11 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXLAAxcella HealthN/AN/AN/AN/AN/AMIROMiromatrix MedicalN/AN/AN/AN/AN/AOKYOOKYO PharmaN/AN/AN/AN/AN/APLURPluriN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXLAAxcella HealthN/A0.800.80MIROMiromatrix Medical0.023.463.46OKYOOKYO PharmaN/AN/AN/APLURPluri3.697.127.12OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXLAAxcella Health65.07%MIROMiromatrix Medical29.38%OKYOOKYO Pharma2.97%PLURPluri16.59%Insider OwnershipCompanyInsider OwnershipAXLAAxcella Health2.20%MIROMiromatrix Medical5.20%OKYOOKYO Pharma40.46%PLURPluri24.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAXLAAxcella Health112.95 million2.88 millionOptionableMIROMiromatrix Medical7627.42 million25.99 millionOptionableOKYOOKYO Pharma828.83 million17.17 millionNot OptionablePLURPluri1235.18 million3.93 millionOptionableAXLA, MIRO, OKYO, and PLUR HeadlinesSourceHeadlineTenaya Therapeutics (NASDAQ:TNYA) and Pluri (NASDAQ:PLUR) Financial Reviewamericanbankingnews.com - April 18 at 1:36 AMPackers will face the Eagles in Brazil's first NFL game evermsn.com - April 11 at 1:55 AMPluri Inc. announces breakthrough in immune cell therapy productionuk.investing.com - April 10 at 10:53 AMPluri stock jumps 9% on US patent for immune cell productionmsn.com - April 8 at 3:46 PMPluri launches manufacturing division as cell therapy pipeline progressespharmaceutical-technology.com - April 8 at 3:46 PMBreakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Methodglobenewswire.com - April 8 at 7:00 AMPLUR Stock Earnings: Pluri Reported Results for Q4 2023investorplace.com - April 3 at 3:01 PMHere is the list of companies splitting on April 1:goodreturns.in - April 1 at 9:41 AMReAlta signs deal with NIAID to develop drug for radiation poisoningmsn.com - March 29 at 4:35 PMPluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferencesfinance.yahoo.com - March 28 at 10:29 AMPluri's Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferencesglobenewswire.com - March 28 at 7:15 AMPluri Inc. Announces 1-for-8 Reverse Share Splitglobenewswire.com - March 27 at 7:00 AMPluri's Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Reportglobenewswire.com - March 21 at 7:00 AMEngage with Pluri's Talent: Exciting Conference Appearances Aheadglobenewswire.com - March 19 at 4:00 AMTruth, justice & freedom in a pluri-anthropological worldeuropean-news-agency.de - March 18 at 6:24 PMYour next cup of coffee may come from a labisrael21c.org - March 18 at 8:23 AMPluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturingglobenewswire.com - March 14 at 7:00 AMImproving Cell Therapy Supply Chainsgenengnews.com - March 13 at 4:38 PMPluri Receives First-Ever Patent for 3D Bioreactor Technology in Plant Cell Cultivationvegconomist.com - March 12 at 5:34 PMIsraeli Startup Gets Patent For 3D Bioreactor To Cultivate Plant Cellsnocamels.com - March 12 at 12:33 PMPluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivationglobenewswire.com - March 11 at 7:00 AMPluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Boardglobenewswire.com - March 6 at 7:00 AMPluri’s Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goalsfinance.yahoo.com - February 28 at 9:36 AMPluri's Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goalsglobenewswire.com - February 28 at 7:00 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAxcella HealthNASDAQ:AXLAAxcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.Miromatrix MedicalNASDAQ:MIROMiromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. The company's proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. It has collaborations with Baxter, CareDx, The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota.OKYO PharmaNASDAQ:OKYOOKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.PluriNASDAQ:PLURPluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.